Polymorphisms in the BRCA1 and ABCB1 genes modulate menopausal hormone therapy associated breast cancer risk in postmenopausal women

Breast Cancer Research and Treatment

Volumn 120, Issue 3, 2010, Pages 727-736

  Abbas, Sascha ^a   Beckmann, Lars ^a   Changclaude, Jenny ^a   Hein, Rebecca ^a   Kropp, Silke ^a   Parthimos, Margie ^a   Dünnebier, Thomas ^a   Hamann, Ute ^a   Brors, Benedikt ^a   Eils, Roland ^a   Zapatka, Marc ^a   Brauch, Hiltrud ^b   Justenhoven, Christina ^b   Flesch Janys, Dieter ^c   Braendle, Wilhelm ^c   Brüning, Thomas ^d   Pesch, Beate ^d   Spickenheuer, Anne ^d   Baisch, Christian ^e   Ko, Yon Dschun ^e   Dahmen, Norbert ^f   more..

^a GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^b UNIVERSITY OF TÜBINGEN   (Germany)

^c UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^d RUHR UNIVERSITY BOCHUM   (Germany)

^e Johanniter Krankenhaus   (Germany)

^f Center for Gynaecology Obstetrics and Paediatrics) ^*  (Germany)

Author keywords

Cell cycle regulators; Cytokines and cytokine receptors; Hormone therapy; Polymorphisms; Postmenopausal breast cancer risk; Transporters

Indexed keywords

AURORA A KINASE; BRCA1 PROTEIN; CYCLIN DEPENDENT KINASE INHIBITOR 1A; CYTOKINE; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN; INTERLEUKIN 6; MULTIDRUG RESISTANCE PROTEIN 1; PROGESTERONE; PROTEIN LTA; PROTEIN P53; SOMATOMEDIN BINDING PROTEIN 3; SOMATOMEDIN C RECEPTOR; TRANSFORMING GROWTH FACTOR BETA1; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ARTICLE; BREAST CANCER; CANCER RISK; CELL CYCLE REGULATION; DNA MODIFICATION; DNA POLYMORPHISM; GENE FREQUENCY; GENETIC VARIABILITY; GENOTYPE; HETEROZYGOSITY; HOMOZYGOSITY; HORMONAL THERAPY; HORMONE RESPONSE; HUMAN; INHERITANCE; POSTMENOPAUSE; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR; TREATMENT DURATION;

AGED; ALLELES; BREAST NEOPLASMS; CASE-CONTROL STUDIES; ESTROGEN REPLACEMENT THERAPY; ESTROGENS; FEMALE; GENES, BRCA1; GENETIC ASSOCIATION STUDIES; GENOTYPE; GERMANY; HAPLOTYPES; HORMONE REPLACEMENT THERAPY; HUMANS; MIDDLE AGED; ODDS RATIO; POLYMORPHISM, SINGLE NUCLEOTIDE; POSTMENOPAUSE; PROGESTINS; RISK FACTORS;

EID: 77950866261     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-009-0489-8     Document Type: Article

References (53)

1. Lo PK, Sukumar S (2008) Epigenomics and breast cancer. Pharmacogenomics 9: 1879-1902
2. Lichtenstein P, Holm NV, Verkasalo PK, Iliadou A, Kaprio J, Koskenvuo M, Pukkala E, Skytthe A, Hemminki K (2000) Environmental and heritable factors in the causation of cancer -analyses of cohorts of twins from Sweden, Denmark, and Finland. N Engl J Med 343: 78-85 (Pubitemid 30451850)
3. Beral V (2003) Breast cancer and hormone-replacement therapy in the million women study. Lancet 362: 419-427 (Pubitemid 36999703)
4. Rossouw JE, Anderson GL, Prentice RL et al (2002) Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the women's health initiative randomized controlled trial. JAMA 288: 321-333
5. Flesch-Janys D, Slanger T, Mutschelknauss E, Kropp S, Obi N, Vettorazzi E, Braendle W, Bastert G, Hentschel S, Berger J, Chang-Claude J (2008) Risk of different histological types of postmenopausal breast cancer by type and regimen of menopausal hormone therapy. Int J Cancer 123: 933-941 (Pubitemid 352032424)
6. Newcomb PA, Titus-Ernstoff L, Egan KM, Trentham-Dietz A, Baron JA, Storer BE, Willett WC, Stampfer MJ (2002) Postmenopausal estrogen and progestin use in relation to breast cancer risk. Cancer Epidemiol Biomarkers Prev 11: 593-600 (Pubitemid 34760816)
7. Ross RK, Paganini-Hill A, Wan PC, Pike MC (2000) Effect of hormone replacement therapy on breast cancer risk: estrogen versus estrogen plus progestin. J Natl Cancer Inst 92: 328-332 (Pubitemid 30117736)
8. Schairer C, Lubin J, Troisi R, Sturgeon S, Brinton L, Hoover R (2000) Menopausal estrogen and estrogen-progestin replacement therapy and breast cancer risk. JAMA 283: 485-491. (Pubitemid 30062864)
9. Seeger H, Mueck AO (2008) Are the progestins responsible for breast cancer risk during hormone therapy in the postmenopause? Experimental vs. clinical data. J Steroid Biochem Mol Biol 109: 11-15
10. Eliassen AH, Missmer SA, Tworoger SS, Spiegelman D, Barbieri RL, Dowsett M, Hankinson SE (2006) Endogenous steroid hormone concentrations and risk of breast cancer among premenopausal women. J Natl Cancer Inst 98: 1406-1415 (Pubitemid 44530717)
11. Key T, Appleby P, Barnes I, Reeves G (2002) Endogenous sex hormones and breast cancer in postmenopausal women: reanalysis of nine prospective studies. J Natl Cancer Inst 94: 606-616 (Pubitemid 34498648)
12. The MARIE-GENICA Consortium on Genetic Susceptibility for Menopausal Hormone Therapy Related Breast Cancer Risk (2009) Genetic polymorphisms in phase I and phase II enzymes and breast cancer risk associated with menopausal hormone therapy in postmenopausal women. Breast Cancer Res Treat. doi: 10.1007/s10549-009-0407-0
13. Brandt B, Hermann S, Straif K, Tidow N, Buerger H, ChangClaude J (2004) Modification of breast cancer risk in young women by a polymorphic sequence in the egfr gene. Cancer Res 64: 7-12 (Pubitemid 38114073)
14. Cox A, Dunning AM, Garcia-Closas M et al (2007) A common coding variant in CASP8 is associated with breast cancer risk. Nat Genet 39: 352-358
15. Cui Y, Shu XO, Cai Q, Jin F, Cheng JR, Cai H, Gao YT, Zheng W (2005) Association of breast cancer risk with a common functional polymorphism (Asp327Asn) in the sex hormonebinding globulin gene. Cancer Epidemiol Biomarkers Prev 14: 1096-1101 (Pubitemid 40656453)
16. Driver KE, Song H, Lesueur F, Ahmed S, Barbosa-Morais NL, Tyrer JP, Ponder BA, Easton DF, Pharoah PD, Dunning AM (2008) Association of single-nucleotide polymorphisms in the cell cycle genes with breast cancer in the British population. Carcinogenesis 29: 333-341 (Pubitemid 351359672)
17. Dunning AM, Ellis PD, McBride S et al (2003) A transforming growth factorbetal signal peptide variant increases secretion in vitro and is associated with increased incidence of invasive breast cancer. Cancer Res 63: 2610-2615 (Pubitemid 36605203)
18. Ewart-Toland A, Dai Q, Gao YT et al (2005) Aurora-A/STK15 T+91A is a general low penetrance cancer susceptibility gene: a meta-analysis of multiple cancer types. Carcinogenesis 26: 1368-1373
19. Gaudet MM, Egan KM, Lissowska J et al (2007) Genetic variation in tumor necrosis factor and lymphotoxin-alpha (TNF-LTA) and breast cancer risk. Hum Genet 121: 483-490 (Pubitemid 46554685)
20. Johnson N, Fletcher O, Palles C et al (2007) Counting potentially functional variants in BRCA1, BRCA2 and ATM predicts breast cancer susceptibility. Hum Mol Genet 16: 1051-1057
21. Langerod A, Bukholm IR, Bregard A, Lonning PE, Andersen TI, Rognum TO, Meling GI, Lothe RA, Borresen-Dale AL (2002) The TP53 codon 72 polymorphism may affect the function of TP53 mutations in breast carcinomas but not in colorectal carcinomas. Cancer Epidemiol Biomarkers Prev 11: 1684-1688 (Pubitemid 36020025)
22. Nelson SE, Gould MN, Hampton JM, Trentham-Dietz A (2005) A case-control study of the HER2 Ile655Val polymorphism in relation to risk of invasive breast cancer. Breast Cancer Res 7: R357-R364
23. Sjalander A, Birgander R, Hallmans G, Cajander S, Lenner P, Athlin L, Beckman G, Beckman L (1996) p53 polymorphisms and haplotypes in breast cancer. Carcinogenesis 17: 1313-1316 (Pubitemid 26196343)
24. Slattery ML, Curtin K, Baumgartner R, Sweeney C, Byers T, Giuliano AR, Baumgartner KB, Wolff RR (2007) IL6, aspirin, nonsteroidal anti-inflammatory drugs, and breast cancer risk in women living in the southwestern United States. Cancer Epidemiol Biomarkers Prev 16: 747-755 (Pubitemid 46650577)
25. Thompson DJ, Healey CS, Baynes C et al (2008) Identification of common variants in the SHBG gene affecting sex hormonebinding globulin levels and breast cancer risk in postmenopausal women. Cancer Epidemiol Biomarkers Prev 17: 3490-3498
26. Turgut S, Yaren A, Kursunluoglu R, Turgut G (2007) MDR1 C3435T polymorphism in patients with breast cancer. Arch Med Res 38: 539-544 (Pubitemid 46873813)
27. Wen W, Gao YT, Shu XO, Yu H, Cai Q, Smith JR, Zheng W (2005) Insulin-like growth factor-I gene polymorphism and breast cancer risk in Chinese women. Int J Cancer 113: 307-311. (Pubitemid 39628323)
28. Xie D, Shu XO, Deng Z, Wen WQ, Creek KE, Dai Q, Gao YT, Jin F, Zheng W (2000) Population-based, case-control study of HER2 genetic polymorphism and breast cancer risk. J Natl Cancer Inst 92: 412-417 (Pubitemid 30154823)
29. Zubor P, Lasabova Z, Hatok J, Standova A, Danko J (2007) A polymorphism C3435T of the MDR-1 gene associated with smoking or high body mass index increases the risk of sporadic breast cancer in women. Oncol Rep 18: 211-217
30. Pesch B, Ko Y, Brauch H et al (2005) Factors modifying the association between hormone-replacement therapy and breast cancer risk. Eur J Epidemiol 20: 699-711 (Pubitemid 41266867)
31. Justenhoven C, Pierl CB, Haas S et al (2008) The CYP1B1- 1358-GG genotype is associated with estrogen receptor-negative breast cancer. Breast Cancer Res Treat 111: 171-177 (Pubitemid 352009231)
32. Barrett JC, Fry B, Mailer J, Daly MJ (2005) Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics 21: 263-265 (Pubitemid 40202029)
33. Gabriel SB, Schaffner SF, Nguyen H et al (2002) The structure of haplotype blocks in the human genome. Science 296: 2225-2229
34. Obreiter M, Fischer C, Chang-Claude J, Beckmann L (2005) SDMinP: a program to control the family wise error rate using step-down minP adjusted P-values. Bioinformatics 21: 3183-3184
35. Ambudkar SV, Dey S, Hrycyna CA, Ramachandra M, Pastan I, Gottesman MM (1999) Biochemical, cellular, and pharmacological aspects of the multidrug transporter. Annu Rev Pharmacol Toxicol 39: 361-398 (Pubitemid 29222564)
36. Gottesman MM, Pastan I, Ambudkar SV (1996) P-glycoprotein and multidrug resistance. Curr Opin Genet Dev 6: 610-617
37. Barnes KM, Dickstein B, Cutler GB Jr, Fojo T, Bates SE (1996) Steroid treatment, accumulation, and antagonism of P-glycoprotein in multidrug-resistant cells. Biochemistry 35: 4820-4827 (Pubitemid 26126700)
38. Kim. WY, Benet LZ (2004) P-glycoprotein (P-gp/MDR1)-mediated efflux of sex-steroid hormones and modulation of P-gp expression in vitro. Pharm Res 21: 1284-1293
39. Hamilton KO, Yazdanian MA, Audus KL (2001) Modulation of P-glycoprotein activity in Calu-3 cells using steroids and betaligands. Int J Pharm 228: 171-179 (Pubitemid 32905376)
40. Ichikawa-Haraguchi M, Sumizawa T, Yoshimura A, Furukawa T, Hiramoto S, Sugita M, Akiyama S (1993) Progesterone and its metabolites: the potent inhibitors of the transporting activity of P-glycoprotein in the adrenal gland. Biochim Biophys Acta 1158: 201-208 (Pubitemid 23348994)
41. Brinkmann U, Eichelbaum M (2001) Polymorphisms in the ABC drug transporter gene MDRI, Pharmacogenomics J 1: 59-64 (Pubitemid 33757984)
42. Gudmundsdottir K, Ashworth A (2006) The roles of BRCA1 and BRCA2 and associated proteins in the maintenance of genomic stability. Oncogene 25: 5864-5874 (Pubitemid 44453442)
43. Welcsh PL, King MC (2001) BRCA1 and BRCA2 and the genetics of breast and ovarian cancer. Hum Mol Genet 10: 705-713 (Pubitemid 32331579)
44. Yeh S, Hu YC, Rahman M, Lin HK, Hsu CL, Ting HJ, Kang HY, Chang C (2000) Increase of androgen-induced cell death and androgen receptor transactivation by BRCA1 in prostate cancer cells. Proc Natl Acad Sci USA 97: 11256-11261
45. Scully R, Chen J, Plug A, Xiao Y, Weaver D, Feunteun J, Ashley T, Livingston DM (1997) Association of BRCA1 with Rad51 in mitotic and meiotic cells. Cell 88: 265-275 (Pubitemid 28015875)
46. Tommasi S, Pi lato B, Pinto R, Monaco A, Bruno M, Campana M, Digennaro M, Schittulli F, Lacalamita R, Paradiso A (2008) Molecular and in silico analysis of BRCA1 and BRCA2 variants. Mutat Res 644: 64-70
47. Schnyder S, Du NT, Le HB, Singh S, Loredo GA, Vaughan AT (2009) Estrogen treatment induces MLL aberrations in human lymphoblastoid cells. Leuk Res 33: 1400-1404
48. Tsutsui T, Tamura Y, Yagi E, Barrett JC (2000) Involvement of genotoxic effects in the initiation of estrogen-induced cellular transformation: studies using Syrian hamster embryo cells treated with 17beta-estradiol and eight of its metabolites. Int J Cancer 86: 8-14 (Pubitemid 30133980)
49. Fan S, Wang J, Yuan R, Ma Y, Meng Q, Erdos MR, Pestell RG, Yuan F, Auborn KJ, Goldberg ID, Rosen EM (1999) BRCA1 inhibition of estrogen receptor signaling in transfected cells. Science 284: 1354-1356 (Pubitemid 29289660)
50. Fan S, Ma YX, Wang C et al (2001) Role of direct interaction in BRCA1 inhibition of estrogen receptor activity. Oncogene 20: 77-87 (Pubitemid 32142340)
51. Slattery ML, Sweeney C, Wolff R, Herrick J, Baumgartner K, Giuliano A, Byers T (2007) Genetic variation in IGF1, IGFBP3, IRS1, IRS2 and risk of breast cancer in women living in South-western United States. Breast Cancer Res Treat 104: 197-209 (Pubitemid 47084224)
52. Diergaarde B, Potter JD, Jupe ER, Manjeshwar S, Shimasaki CD, Pugh TW, DeEreese DC, Gramling BA, Evans I, White E (2008) Polymorphisms in genes involved in sex hormone metabolism, estrogen plus progestin hormone therapy use, and risk of postmenopausal breast cancer. Cancer Epidemiol Biomarkers Prev 17: 1751-1759
53. Patel AV, Cheng I, Canzian F et al (2008) IGF-1, IGFBP-1, and IGFBP-3 polymorphisms predict circulating IGF levels but not breast cancer risk: findings from the Breast and Prostate Cancer Cohort Consortium (BPC3). PLoS ONE 3: e2578